JPMorgan raised the firm’s price target on Johnson & Johnson to $250 from $225 and keeps a Neutral rating on the shares. The firm cites its increased Tremfya estimates for the target boost. The recent ramp of Tremfya in inflammatory bowel disease has driven outperformance for the product, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Best ETFs to Invest In, According to AI Analyst, 3/4/2026
- Johnson & Johnson Stock Forecast: Trending Analyst Sees Limited Upside
- Johnson & Johnson says FDA grants Fast Track designation to nipocalimab
- Johnson & Johnson price target raised to $253 from $227 at BofA
- Balanced Outlook on Johnson & Johnson: Higher Oncology-Driven Estimates but Limited Upside Justify Hold Rating